Sustained gains with long-term Vyvgart use seen in ADAPT+ trial
Repeat cycles of Vyvgart (efgartigimod alfa-fcab) led to consistent clinical improvements among generalized myasthenia gravis (gMG) patients, regardless…
Articles by Lindsey Shapiro, PhD
Rystiggo, Zilbrysq earn EU approvals for adults with gMG
The European Commission has approved Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of certain adults…
2 types of anesthesia found safe, effective for surgery in MG: Study
Both propofol and sevoflurane — two types of agents for anesthesia management — were found to be safe and effective…
Certain barriers to healthcare seen to worsen gMG economic burden
People living with generalized myasthenia gravis (gMG) in the U.S. who experience certain barriers to healthcare reported major economic…
Zilucoplan found effective for gMG in Japanese patients in analyses
Daily treatment with zilucoplan was tied to meaningful reductions in symptom severity among the subgroup of Japanese generalized…
Worse disease seen for certain pediatric myasthenia gravis patients
A more severe disease course was seen among pediatric myasthenia gravis (MG) patients with antibodies against acetylcholine receptors (AChRs)…
European panel recommends under-the-skin efgartigimod for gMG
A European Medicines Agency (EMA) committee has recommended the approval of Argenx’s under-the-skin, or subcutaneous, formulation of efgartigimod as…
Cell-based assay better at detecting MG-driving antibodies
A cell-based assay for detecting myasthenia gravis (MG)-causing antibodies in the blood results in greater diagnostic accuracy than two…
Most childhood-onset MG patients have good prognosis: Study in China
Most people with childhood-onset myasthenia gravis (CMG) experience milder clinical symptoms and a better prognosis than those with adult…
Approved gMG therapy Rystiggo now available to adults in US
The targeted generalized myasthenia gravis (gMG) treatment Rystiggo (rozanolixizumab-noli) is now commercially available by prescription in the U.S.